October 17, Paris, Sanofi and Orano Med (a subsidiary of Orano Group)Orano Med, a pioneer in the development of oncology-targeted alpha therapies, has reached an agreement to combine their expertise in combating rare cancers, further accelerating the development of the next generation of radioligand drugs.Sanofi and Orano will collaborate in Orano Med (Orano Med) and the radioligand pipeline, a new entity has been established as an investment to operate under the Orano Med brand. This entity is dedicated to the discovery, design, and clinical development of next-generation radioligand therapies (RLT) based on the alpha-emitting isotope lead-212 (212Pb). Last month, Sanofi announced its collaboration withOrano Medand its partner RadioMedix sign an exclusive licensing agreement to advance radioligand therapy (RLT) for rare cancers, focusing on the late-stage project AlphaMedix™ (A Drug Based on Lead-212). Sanofi paid an upfront payment of 100 million euros (approximately 110 million US dollars), with total sales milestones of up to about 220 million euros (242 million US dollars), as well as tiered royalties. Sanofi plans to drive commercialization, while Orano Med is responsible for manufacturing.According to the terms of the agreement, Sanofi will make a 300 million euro (approximately 324 million US dollars) equity investment, accounting for the new entity.Orano MedApproximately 16% of the equity, valued at 1.9 billion euros (approximately 2.055 billion US dollars).Targeted Alpha Therapy relies on a simple concept: combining the ability of biological vectors to target cancer cells with the short-range, high-energy cell-killing power of alpha-emitting isotopes. The vector directs the isotope to target cancer cells expressing specific markers, even if they have spread throughout the body. This unique mechanism of action aims to damage or destroy targeted cancer cells while limiting effects on nearby healthy cells. This novel approach to precision medicine seeks to transform the standard of care for some rare cancers, extending patients' lives and improving their quality of life.
CEO of SanofiPaul Hudson said:"We are thrilled to partner with Orano to establish a pioneering French company that combines our respective expertise in biopharmaceuticals and nuclear technology to drive breakthrough advancements in the fight against cancer. As a French biopharmaceutical company, we are firmly committed to promoting and advancing innovation in France. This collaboration is part of a broader effort to strengthen our relationships within the scientific communities in France and around the world, with the goal of accelerating the development of cutting-edge treatments for patients."CEO of Orano GroupNicolas Maes said:"The success of Orano Med is an example of our group's diversification beyond our core nuclear business. By applying our expertise in nuclear materials to fields such as targeted alpha therapy, we demonstrate that nuclear technology can have a positive social impact not only on energy and climate but also on human health. This innovation reflects Orano's commitment to exploring new opportunities and taking bold steps to address some of the world's most pressing challenges."Sanofi's investment will be further strengthenedOrano Med, enabling the company to leverage its unique capabilities in the discovery and development of lead-212-based therapies to accelerate the development of its pipeline. Orano Med has also developed a highly differentiated global industrial platform, which, with its extensive inventory of raw materials and patented manufacturing processes, will ensure independent, reliable, and scalable access to lead-212-based therapies for patients worldwide.In its endeavor to become a global leader in immunoscience, Sanofi remains committed to advancing innovation in oncology. The pipeline is being reshaped and prioritized, leveraging expertise in immunoscience to drive progress. Efforts are focused on difficult-to-treat cancers, including selected hematologic malignancies and solid tumors with significant unmet needs, such as rare cancers like multiple myeloma, acute myeloid leukemia, and certain types of lymphoma, as well as gastrointestinal and lung cancers.
Follow the official account below to see the world!
